Capricor Therapeutics, Inc.
CAPR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $22,270 | $25,178 | $2,551 | $245 |
| % Growth | -11.5% | 886.8% | 941.8% | – |
| Cost of Goods Sold | $49,969 | $36,448 | $21,817 | $0 |
| Gross Profit | -$27,698 | -$11,270 | -$19,265 | $245 |
| % Margin | -124.4% | -44.8% | -755.1% | 100% |
| R&D Expenses | $49,969 | $36,448 | $21,817 | $13,571 |
| G&A Expenses | $14,867 | $12,808 | $10,432 | $7,612 |
| SG&A Expenses | $14,867 | $12,808 | $10,432 | $7,612 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$49,969 | -$36,448 | -$21,817 | $0 |
| Operating Expenses | $14,867 | $12,808 | $10,432 | $21,183 |
| Operating Income | -$42,565 | -$24,078 | -$29,697 | -$20,938 |
| % Margin | -191.1% | -95.6% | -1,163.9% | -8,549.9% |
| Other Income/Exp. Net | $2,098 | $1,790 | $678 | $916 |
| Pre-Tax Income | -$40,467 | -$22,288 | -$29,020 | -$20,023 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$40,467 | -$22,288 | -$29,020 | -$20,023 |
| % Margin | -181.7% | -88.5% | -1,137.4% | -8,175.9% |
| EPS | -1.15 | -0.83 | -1.18 | -0.87 |
| % Growth | -38.6% | 29.7% | -35.6% | – |
| EPS Diluted | -1.15 | -0.83 | -1.18 | -0.87 |
| Weighted Avg Shares Out | 35,219 | 26,778 | 24,553 | 23,089 |
| Weighted Avg Shares Out Dil | 35,219 | 26,778 | 24,553 | 23,089 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,203 | $1,729 | $522 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1,425 | $1,069 | $533 | $246 |
| EBITDA | -$41,140 | -$23,009 | -$29,164 | -$20,693 |
| % Margin | -184.7% | -91.4% | -1,143% | -8,449.5% |